$Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer$
QR Code

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer

Patients with refractory metastatic triple-negative breast cancer (mTNBC) and symptomatic brain metastases have poor prognosis and are challenging to treat. The addition of an programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitor (pembrolizumab or atezolizumab) to first lin...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hongyuan Zhao, Weijie Ma, Ruben C. Fragoso, Griffith R. Harsh IV, Arya Ashok, Tianhong Li
Format:	article
Language:	EN
Published:	Elsevier 2021
Subjects:	Multidisciplinary Immune checkpoint inhibitor Pdj amplification Triple-negative breast cancer Brain metastasis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/b0207e3a22944f94890d61ef2e6ba3ed
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer

Similar Items